Van Gorp T, Cibula D, Lv W, Backes F, Ortaç F, Hasegawa K, Lindemann K, Savarese A, Laenen A, Kim YM, Bodnar L, Barretina-Ginesta MP, Gilbert L, Pothuri B, Chen X, Flores MB, Levy T, Colombo N, Papadimitriou C, Buchanan T, Hanker LC, Eminowicz G, Rob L, Black D, Lichfield J et al. (2024)
ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer
Ann Oncol (in press)
DOI 10.1016/j.annonc.2024.08.2242, PubMed 39284383

Bischof K, Cremaschi A, Eroukhmanoff L, Landskron J, Flage-Larsen LL, Gade A, Bjørge L, Urbanucci A, Taskén K (2024)
Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways
Mol Oncol (in press)
DOI 10.1002/1878-0261.13726, PubMed 39245677

Rios-Doria E, Nobre SP, Sassine D, Glaser G, Eriksson AG, Ataseven B, du Bois A, Makker V, Alektiar K, Leitao MM, Abu-Rustum NR, Mueller JJ (2024)
Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium
Gynecol Oncol, 190, 236-242 (in press)
DOI 10.1016/j.ygyno.2024.08.019, PubMed 39243699